PLX 200

Drug Profile

PLX 200

Alternative Names: PLX200

Latest Information Update: 08 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Polaryx Therapeutics
  • Class Small molecules
  • Mechanism of Action Tripeptidyl-peptidase 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuronal ceroid lipofuscinosis
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Neuronal ceroid lipofuscinosis

Most Recent Events

  • 08 Aug 2017 PLX 200 receives Orphan Drug status for Neuronal ceroid lipofuscinosis in USA
  • 08 May 2017 PLX 200 is available for licensing as of 08 May 2017. (Polaryx Therapeutics pipeline, May 2017)
  • 08 May 2017 Preclinical trials in Neuronal ceroid lipofuscinosis in USA (PO) before May 2017 (Polaryx Therapeutics pipeline, May 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top